News

New collaboration will focus on analyzing and improving guidelines-based utilization of precision medicine to better support oncologists and cancer patients.

This partnership, aimed at making precision medicine more accessible for patients and community oncologists, is actively supporting clinicians at Alabama Cancer Care.

This article from the AJMC - The American Journal of Managed Care captures how we’re solving the last mile in precision medicine for clinicians and patients. Our unique combination of artificial intelligence (AI) and medical expertise makes the difference.

Avestria Ventures invested in Clarified Precision Medicine because the company fills a critical oncology need with an advanced solution and, in the process, bridges the gap between genomic testing and care, making genomically-informed precision medicine available, accessible, and actionable.

Clarified Precision Medicine on Tuesday said it has raised $1.2 million in a seed financing round, which it will put toward advancing its virtual molecular tumor board model and help more patients and providers gain access to guidelines-based precision oncology treatments.

Clarified Precision Medicine, the only company that provides oncologists with prioritized therapy options via a combination of algorithmic testing and physician oversight, announced that it closed on its seed round of $1.2 million led by Avestria Ventures, with participation from Joyance Partners, both early-stage funds focused on improving health. The company also named Rajni Natesan, MD, MBA as its Chief Executive Officer.